SETD2 and neoplasm: In contrast, AZD1775 treatment of tumors generated from SETD2-proficient U2OS cells did not have any significant effect on tumor growth (tumor size at day 12 = 257.5 ± 19.3 mm3 versus 292.5 ± 34.3 mm3, p = 0.37) (Figures 5A and 5B).